Evidence That D-dimer Levels Predict Subsequent Thromboembolic and Cardiovascular Events in Patients with Atrial Fibrillation during Oral Anticoagulant.

Slides:



Advertisements
Similar presentations
Atrial Fibrillation Cardiovascular ISCEE 26th October 2010.
Advertisements

ROCKET-AF Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial.
Prosthetic Valve; Anticoagulation After ICH Dr.Tahsin.N.
Sumeet Subherwal, Richard G. Bach, Anita Y. Chen, Brian F. Gage, Sunil V. Rao, Tracy Y. Wang, W. Brian Gibler, E. Magnus Ohman, Matthew T. Roe, Eric D.
Role of Cilostazol in Stroke Prevention Philippine Heart Association 43 rd Annual Convention & Scientific Meeting Landmark Trials Session May 24, 2012.
Valsartan Antihypertensive Long-Term Use Evaluation Results
Etiology distribution of patients with atrial fibrilation by echocardiography: results from a prospective study in 3755 adults Enes Abdovic Cantonal Hospital.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Jiang He, Yonghong Zhang, Tan Xu, Weijun Tong, Shaoyan Zhang,
Morbidity & Mortality: 2012 Chart Book on Cardiovascular, Lung, and
  Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban Target
Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
The Long Term Multi-Center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) study To reviewers and moderators: These.
Secondary prevention after a TIA or ischemic stroke.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Randomized, double-blind, multicenter, controlled trial.
Bridging Oral Anticoagulation with Low Molecular Weight Heparin: Experience in 367 Patients with Renal Insufficiency Heyder Omran, Giso von der Recke,
Anticoagulation Transitions: Perioperative Care Alan Brush, MD, FACP Clinical Co-Director, Anticoagulation Management Service Harvard Vanguard Medical.
ACTIVE Clopidogrel plus Aspirin versus Aspirin in Patients Unsuitable for Warfarin.
Multiple risk factors raise ischaemic stroke risk comparable to AF in the elderly: A large Chinese insurance analysis from 425,600 Chinese individuals.
Specialized Atrial Fibrillation Clinic reduces cardiovascular morbidity and mortality in patients with atrial fibrillation Jeroen ML Hendriks, MSc Robert.
Stage 4 CKD presentation in patients over 75 Years Old differs from that in patients less than 75 Years of Age Hiromichi Suzuki, Tsutomu Inoue,Tomohiro.
Global Variations in the 1-year Rates of Death and Stroke in Patients Presenting to the Emergency Department with Atrial Fibrillation Results from the.
Dodson Thompson, DO Northlakes Community Clinic Minong, WI.
10 May 2005 CASES - Original article available at CASES (Canadian Alteplase for Stroke Effectiveness Study) The CASES Investigators.
Red Cell Distribution Width (RDW) as a Novel Prognostic Marker in Heart Failure: Data from the CHARM Program and the Duke Databank.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Terutroban versus aspirin in Patients with Cerebral Ischaemic Events (PREFORM): a Randomized, Double- blind Parallel-group Trial Daniel Wells Mercer University.
Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Nonvalvular Atrial Fibrillation SPORTIF V Trial Presented at American.
ALI R. RAHIMI, BOBBY WRIGHTS, MD, HOSSEIN AKHONDI, MD & CHRISTIAN M. RICHARD, MSC Clinical Correlation Between Effective Anticoagulants & Risk of Stroke:
Relationship between total cholesterol and 90-day mortality after acute myocardial infarction in patients not on statins Rishi Parmar 2 nd year Medicine.
Update in ESC: Dabigatran among OAC
Long-Term Outcomes in Patients Undergoing Coronary Stenting on Dual Oral Antiplatelet Treatment Requiring Oral Anticoagulant Therapy R. Rossini, G. Musumeci,
Higher Incidence of Venous Thromboembolism (VTE) in the Outpatient versus Inpatient Setting Among Patients with Cancer in the United States Khorana A et.
Etiological Distribution of Chronic and Transient Atrial Fibrillation in Patients at Cantonal Hospital Zenica Enes Abdović 10 yrs Prospective Study, 29.
Presented by Renato D. Lopes, MD, PhD, Duke Clinical Research Institute, Duke University, USA for the ARISTOTLE investigators. Efficacy and Safety of Apixaban.
Preoperative Hemoglobin A1c and the Occurrence of Atrial Fibrillation Following On-pump Coronary Artery Bypass surgery in Type-2 Diabetic Patients Akbar.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and.
December 02 1 Vascular mortality: Age-specific hazard ratios for 20 mmHg lower usual SBP deaths at ages
The Risks of Thromboembolism Vs. Recurrent Gastrointestinal Bleeding after Interruption of Systemic Anticoagulation in Hospitalized Inpatients With Gastrointestinal.
Why Treat Patent Forman Ovale Clifford J Kavinsky, MD, PHD Professor of Medicine and pediatrics Associate Director, Center for Congenital and Structural.
R4 문정락 / IC prof. 김진배 Lancet Haematol 2015;2: e150–59.
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D., Jyotsna Garg, M.S., Guohua Pan, Ph.D.,
Objective Bleeding events are grave and sometimes life threatening complications after prosthetic valve replacement, especially in hemodialysis patients.
Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.
Date of download: 7/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Choice of Antithrombotic Therapy for Stroke Prevention.
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Evidence That D-Dimer Levels Predict Subsequent.
Case 66 year old male with PMH of HTN, DM, ESRD on renal replacement TIW, stroke in 2011 with right side residual weakness, atrial fibrillation, currently.
Cardiology Division, Jeju National University Hospital, Jeju, KOREA
History Of Atrial Fibrillation In A First-Degree Relative
Update on the Watchman Device CRT 2010 Washington, DC
How Do We Incorporate Patient Perspectives Into Clinical Trial Design?
Novel oral anticoagulants in comparison with warfarin
ACTIVE A Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.
ATHENA Trial Presented at Heart Rhythm 2008 in San Francisco, USA
Shikhar Agarwal, MD, MPH, Aatish Garg, MD, Akhil Parashar, MD, Lars G
Efficacy and safety outcomes with NOAC compared with warfarin in NOAC patients with 14 457 years of risk and 49 418 warfarin patients with 75 747.
ACC 2003 Late Breaking Trials
Volume 87, Issue 1, Pages (January 2015)
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Procedural Characteristics
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Figure 8. Stroke prevention strategy in patients with AF
The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.
Presentation transcript:

Evidence That D-dimer Levels Predict Subsequent Thromboembolic and Cardiovascular Events in Patients with Atrial Fibrillation during Oral Anticoagulant Therapy Tsuneaki SADANAGA Ueki Hospital, Kumamoto, Japan

【 Purpose 】 Atrial fibrillation is associated with hemostatic abnormality even during oral anticoagulant therapy. Hypothesis: elevated D-dimer levels predict thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy

Control 28 – 457 days ( INR ) Oral anticoagulant therapy decreased D-dimer levels (30 paroxysmal Af, 13 chronic Af, n=43) p < µg/ml 12/43 =28%, however… 29/43 =67% (µg/ml) D-dimer levels

【 Methods 】 Single center, prospective, observational study Patients with atrial fibrillation (269 patients, 74±9 y/o, 152 male, 157 paroxysmal, 20 prosthetic valve) receiving anticoagulant therapy with warfarin are included. Exclusion: aortic aneurysm, deep vein thrombosis, malignancy (terminal stage), non-compliance (dementia) Entry periods: January April 2007 Observational periods: January December 2008 Follow-up duration: 756±221 (1-1091, median: 736) days D-dimer was measured only during entry periods PT-INR was measured every 1-2 month during observational periods

End points 1.Thromboembolic events (cerebral infarction, transient ischemic attack, peripheral embolism) 2.Combined cardiovascular events (thromboembolic events, cerebral hemorrhage, myocardial infarction, cardiovascular death) Secondary analysis Bleeding complications (intracranial bleeding, gastrointestinal bleeding requiring transfusion) The study protocol was approved by the institutional Ethics Committee and informed written consent was obtained from all the patients included in this study.

6 lost to follow Follow-up day → included in the analysis 4 discontinuation of warfarin Follow-up day → included in the analysis 1 bleeding (accidental fall) 3 physician’s decision (no recurrence of pAf) 259 (96%) completed follow-up at the end of observational periods or reached endpoints 【 Follow-up 】

HHD IHD Valve HCM DCM None HHD: hypertensive heart disease, IHD: ischemic heart disease, Valve: valvular heart disease, HCM: hypertrophic cardiomyopathy DCM: dilated cardiomyopathy Underlying heart disease (%)

CHF HBP Age>75y/o DM Stroke Prosthetic Valve Risk Factors for embolism CHF: Congestive heart failure. NYHA ≧ II, HBP: systolic BP ≧ 140, diastolic BP ≧ 90 mmHg, or medication, DM: Diabetes mellitus. fasting blood glucose ≧ 126mg/dl, HbA1c ≧ 6.1%, medication, or insulin use (%)

CHADS2 score distribution C: Congestive heart failure, H: Hypertension, A: Age ≧ 75y/o D: Diabetes mellitus, S: Stroke, * 26 patients. 24: Age ≧ 65y/o (%) * (n=245, 24 valvular AF are excluded)

Relationship between D-dimer levels and PT-INR 0.5µg/ml 63(23%) PT-INR (µg/ml) (86%) D-dimer levels

D-dimer (+) (n= 63) D-dimer (-) (n=206) (≥ 0.5 μg/ml ) ( < 0.5 μg/ml ) p value Gender ( Male,%)5657n.s. Age (y/o)79±872±9p<0.01 Chronic Af (%)4939n.s. INR2.0± ±0.5n.s. D-dimer (μg/ml ) 1.4± ±0.2p<0.01 CHADS2 score (n=245) * 2.7±1.4(n=55)1.7±1.2(n=190)p<0.01 CHF(%)6735p<0.01 Hypertension (%)5257n.s. Age≥ 75y/o (%)7139p<0.01 Diabetes mellitus(%)2523n.s. History of Stroke (%)219p=0.014 【 Characteristics of patients with high D-dimer levels 】 * 24 patients with valvular AF are excluded

【 Determinants of high D-dimer levels by logistic regression analysis 】 Univariate Analysis Genderp=0.86 Chronic Afp=0.16 PT-INR(entry)p=0.36 CHFp<0.01 Hypertensionp=0.54 Age≥75 y/op<0.01 Diabetes mellitusp=0.67 History of strokep<0.01 Multivariate Analysis Odds ratio (95% CI) Age≥75 y/o p< ( ) CHF p< ( ) History of strokep= ( )

【 Results 】 D-dimer (+) D-dimer (-) (n= 63) (n=206) p value Thromboembolic events82p<0.01 Cardiovascular events189p<0.01 Total mortality148p<0.01 Bleeding complications81p<0.01 Thromboembolic events101.8 % /year Cardiovascular events274.8 %/ year Total mortality223.9 %/year Bleeding complications91.6 %/year

Follow-up duration (day) Thromboembolic events D-dimer < 0.5μg/ml (n = 206) Event free rate p < 0.01 (Log rank test) 8 cerebral infarction, 1 transient ischemic attack, 1 peripheral embolism D-dimer ≥ 0.5μg/ml (n = 63)

【 Risk factors for thromboembolic events by Cox proportional hazard analysis 】 Univariate Analysis D-dimerp<0.01 INR<1.5 (at the time of event)p<0.01 Gender p=0.30 CHFp=0.012 Hypertensionp=0.36 Age≥75 y/op=0.36 Diabetes mellitusp=0.60 History of strokep<0.01 Multivariate Analysis Hazard ratio (95% CI) D-dimer p= ( ) History of strokep< ( ) CHF p= ( )

Follow-up duration (day) Combined cardiovascular events D-dimer < 0.5μg/ml (n = 206) p < 0.01 (Log rank test) Event free rate 10 thromboembolisms, 9 deaths from heart failure, 3 sudden deaths, 2 myocardial infarctions, and 3 cerebral hemorrhages D-dimer ≥ 0.5μg/ml (n = 63)

【 Risk factors for combined cardiovascular events by Cox proportional hazard analysis 】 Univariate Analysis D-dimerp<0.01 Genderp=0.35 CHFp<0.01 Hypertensionp=0.45 Age≥75 y/op<0.01 Diabetes mellitusp<0.01 History of strokep<0.01 Multivariate Analysis Hazard ratio (95% CI) D-dimer p< ( ) CHF p< ( ) Diabetes mellitusp= ( ) History of strokep< ( )

Follow-up duration (day) Total mortality D-dimer < 0.5μg/ml (n = 206) D-dimer ≥ 0.5μg/ml (n = 63) Event free rate p < 0.01 (Log rank test) 18 cardiovascular deaths, 3 pneumonias, 1 lung cancer

【 Risk factors for total mortality by Cox proportional hazard analysis 】 Univariate Analysis D-dimerp<0.01 Genderp=0.85 CHFp<0.01 Hypertensionp=0.46 Age≥75 y/op<0.01 Diabetes mellitusp<0.01 History of strokep<0.01 Multivariate Analysis Hazard ratio (95% CI) D-dimer p= ( ) CHF p< ( ) History of strokep< ( ) Diabetes mellitusp= ( ) Age≥75y/op= ( )

Follow-up duration (day) Bleeding complications 4 intracranial hemorrhage, 5 gastrointestinal bleeding requiring transfusion Event free rate D-dimer < 0.5μg/ml (n = 206) p < 0.01 (Log rank test) D-dimer ≥ 0.5μg/ml (n = 63)

【 Risk factors for bleeding complications by Cox proportional hazard analysis 】 Univariate Analysis D-dimerp<0.01 INR>3.0(at the time of bleeding)p<0.01 Gender(female)p=0.054 CHFp=0.33 Hypertensionp=0.98 Agep<0.01 Diabetes mellitusp=0.15 History of strokep<0.01 Multivariate Analysis Hazard ratio (95% CI) D-dimer p< ( ) INR>3.0(at the time of bleeding)p< ( ) Gender(female)p= ( ) History of strokep= ( )

【 Conclusion 】 Persistent elevation of D-dimer Levels despite proper anticoagulant therapy can predict thromboembolic and cardiovascular events in patients with atrial fibrillation Further larger scale, multicenter studies are needed to confirm these findings.